The University of Sydney has announced details of a new partnership designed to further research into ‘sleep-disordered breathing’, which it is hoped will lead to advancements in the diagnosis and treatment of the conditions around the world. ResMed Ltd, a Sydney-based developer of respiratory products including those for sleep disorders, will support the work with a $AU25m funding package.
The work will involve the establishment of two academic chairs, one to focus on sleep-disordered breathing and one to focus on bioinformatics research. Sleep disordered breathing, widely acknowledged as sleep apnoea, is a common disorder that can have negative effects on a sufferer’s health and wellbeing as well as sleep quality, and has been linked to various serious conditions.
“Sleep-disordered breathing is a global health problem affecting one in five adults, with broad and deep implications in other chronic conditions, such as hypertension and heart failure,” said Michael Farrell, ResMed CEO. “With this partnership, we look forward to the University’s research revealing new information on how to battle this costly and life-threatening condition.”
On the land and waters that we sleep, we walk, and we live, we acknowledge the Traditional Owners and Custodians of these lands. We pay respects to Elders past, present and emerging, and recognise their connection to the land.
Copyright © Ergoflex™ 2024
Ergoflex Australia, trading name of EAU Pty Ltd. 7/2 Sabre Close, Anambah Business Park, Rutherford, NSW, 2320 ABN: 85 141 058 380